Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report)’s share price gapped down prior to trading on Monday . The stock had previously closed at $52.69, but opened at $49.97. Tarsus Pharmaceuticals shares last traded at $46.70, with a volume of 205,404 shares.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the company. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $54.20.
Get Our Latest Stock Analysis on Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Stock Performance
Hedge Funds Weigh In On Tarsus Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC grew its position in Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after acquiring an additional 698,712 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after purchasing an additional 420,057 shares during the last quarter. Millennium Management LLC boosted its holdings in Tarsus Pharmaceuticals by 1,259.3% in the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock worth $9,475,000 after purchasing an additional 322,942 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in Tarsus Pharmaceuticals during the third quarter worth $10,587,000. Finally, Vestal Point Capital LP acquired a new position in Tarsus Pharmaceuticals during the third quarter worth $7,565,000. Institutional investors own 90.01% of the company’s stock.
Tarsus Pharmaceuticals Company Profile
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Read More
- Five stocks we like better than Tarsus Pharmaceuticals
- What Are Earnings Reports?
- 3 REITs With Big Dividend Growth and Sustainable Payouts
- What is the Shanghai Stock Exchange Composite Index?
- Can Integrated Healthcare Stocks Succeed in Public Markets?
- How to Buy Cheap Stocks Step by Step
- What Lucid’s Partnership With SoundHound Means for LCID Stock
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.